

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 1, 2026

BD Biosciences

RRID:SCR_013311

Type: Tool

Proper Citation

BD Biosciences (RRID:SCR_013311)

Resource Information

URL: <http://www.bdbiosciences.com/us/home>

Proper Citation: BD Biosciences (RRID:SCR_013311)

Description: An Antibody supplier

Synonyms: BD Biosciences - Discovery Labware

Resource Type: commercial organization, antibody supplier, reagent supplier, material resource

Resource Name: BD Biosciences

Resource ID: SCR_013311

Alternate IDs: nlx_152292

Record Creation Time: 20220129T080315+0000

Record Last Update: 20260801T190458+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences.

No alerts have been found for BD Biosciences.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 79969 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Gao B, et al. (2026) Sox2-overexpressing neural stem cells alleviate ventricular enlargement and neurological dysfunction in posthemorrhagic hydrocephalus. *Neural regeneration research*, 21(2), 769.

Ramamoorthi G, et al. (2025) Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells. *Cancer immunology research*, 13(5), 729.

Chen Y, et al. (2025) A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. *Cancer research*, 85(14), 2753.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Lu Y, et al. (2025) Hypoxia Induces Immunosuppression by Silencing STING in Cancer. *Cancer research*, 85(23), 4664.

Lee SM, et al. (2025) Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 848.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. *Molecular cancer therapeutics*, 24(6), 843.

Nie X, et al. (2025) Bifidobacterium longum NSP001-derived extracellular vesicles ameliorate ulcerative colitis by modulating T cell responses in gut microbiota-(in)dependent manners. *NPJ biofilms and microbiomes*, 11(1), 27.

Li S, et al. (2025) Transdermal microneedle-assisted ultrasound-enhanced CRISPRa system to enable sono-gene therapy for obesity. *Nature communications*, 16(1), 1499.

Kołodziej-Sobczak D, et al. (2025) Design, synthesis, molecular docking and anticancer activity evaluation of methyl salicylate based thiazoles as PTP1B inhibitors. *Scientific reports*, 15(1), 4892.

Zheng S, et al. (2025) Intervening Non-Small-Cell Lung Cancer Progression by Cell Membrane Coated Platycodin D via Regulating Hsa-miR-1246/FUT9/GSK3 β Pathway. *International journal of nanomedicine*, 20, 1661.

Meyer G, et al. (2025) HCMV Variants Expressing ULBP2 Enhance the Function of Human NK Cells via its Receptor NKG2D. *European journal of immunology*, 55(2), e202451266.

Lemay SE, et al. (2025) Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies. *Cell reports. Medicine*, 6(2), 101964.

Fu X, et al. (2025) Cxcl9 modulates aging associated microvascular metabolic and angiogenic dysfunctions in subcutaneous adipose tissue. *Angiogenesis*, 28(2), 17.

Guo R, et al. (2025) Abnormal Expression of Peripheral Blood Leukocyte Surface Markers in Retinopathy of Prematurity Patients. *Journal of multidisciplinary healthcare*, 18, 651.

Gaballa JM, et al. (2025) Interleukin-1 signaling and CD4+ T cells control B cell recruitment to the lungs in chronic beryllium disease. *Frontiers in immunology*, 16, 1479348.

Aw WY, et al. (2025) Dysfunctional mechanotransduction regulates the progression of PIK3CA-driven vascular malformations. *APL bioengineering*, 9(1), 016106.

Das A, et al. (2025) Adenylate cyclase 10 promotes brown adipose tissue thermogenesis. *iScience*, 28(2), 111833.

Lalor R, et al. (2025) An immunoregulatory amphipathic peptide derived from *Fasciola hepatica* helminth defense molecule (FhHDM-1.C2) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(4), e70380.